Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-cash Items (2016 - 2025)

Karyopharm Therapeutics' Non-cash Items history spans 12 years, with the latest figure at $210218.0 for Q4 2025.

  • For Q4 2025, Non-cash Items changed N/A year-over-year to $210218.0; the TTM value through Dec 2025 reached $210218.0, changed N/A, while the annual FY2025 figure was $210218.0, 96.08% down from the prior year.
  • Non-cash Items reached $210218.0 in Q4 2025 per KPTI's latest filing, up from $6000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $2.3 million in Q4 2021 to a low of $6000.0 in Q4 2022.
  • Average Non-cash Items over 3 years is $835072.7, with a median of $210218.0 recorded in 2025.
  • Peak YoY movement for Non-cash Items: tumbled 94.8% in 2021, then plummeted 99.74% in 2022.
  • A 3-year view of Non-cash Items shows it stood at $2.3 million in 2021, then tumbled by 99.74% to $6000.0 in 2022, then skyrocketed by 3403.63% to $210218.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Non-cash Items are $210218.0 (Q4 2025), $6000.0 (Q4 2022), and $2.3 million (Q4 2021).